Subacute sclerosing panencephalitis epidemiology and demographics: Difference between revisions
No edit summary |
m (Changes made per Mahshid's request) |
||
| (8 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Subacute sclerosing panencephalitis}} | {{Subacute sclerosing panencephalitis}} | ||
{{CMG}} | |||
==Overview== | ==Overview== | ||
SSPE is an incredibly rare condition although there is still relatively high incidence in Asia and the Middle East. However, the number of reported cases is declining since the introduction of the measles vaccine — eradication of the measles virus prevents the SSPE mutation and therefore the progression of the disease or even the initial infection itself. | SSPE is an incredibly rare condition although there is still relatively high incidence in Asia and the Middle East. However, the number of reported cases is declining since the introduction of the measles vaccine — eradication of the measles virus prevents the SSPE mutation and therefore the progression of the disease or even the initial infection itself. | ||
==Epidemiology and Demographics== | |||
===Age=== | |||
The disease generally occurs in children and adolescents. | |||
===Gender=== | |||
Males are more often affected than females. | |||
===Developed Countries=== | |||
SSPE has been reported in all parts of the world, but in western countries it is considered a rare disease. Fewer than 10 cases per year are reported in the United States, a dramatic decrease that followed the nationwide measles immunization program. | |||
===Developing Countries=== | |||
In some countries like India, over 2 cases of SSPE per 100,000 people are reported each year. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Needs | [[Category:Needs overview]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Neurological disorders]] | [[Category:Neurological disorders]] | ||
Latest revision as of 18:52, 18 September 2017
|
Subacute sclerosing panencephalitis Microchapters |
|
Differentiating Subacute sclerosing panencephalitis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Subacute sclerosing panencephalitis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Subacute sclerosing panencephalitis epidemiology and demographics |
|
FDA on Subacute sclerosing panencephalitis epidemiology and demographics |
|
CDC on Subacute sclerosing panencephalitis epidemiology and demographics |
|
Subacute sclerosing panencephalitis epidemiology and demographics in the news |
|
Blogs on Subacute sclerosing panencephalitis epidemiology and demographics |
|
Directions to Hospitals Treating Subacute sclerosing panencephalitis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
SSPE is an incredibly rare condition although there is still relatively high incidence in Asia and the Middle East. However, the number of reported cases is declining since the introduction of the measles vaccine — eradication of the measles virus prevents the SSPE mutation and therefore the progression of the disease or even the initial infection itself.
Epidemiology and Demographics
Age
The disease generally occurs in children and adolescents.
Gender
Males are more often affected than females.
Developed Countries
SSPE has been reported in all parts of the world, but in western countries it is considered a rare disease. Fewer than 10 cases per year are reported in the United States, a dramatic decrease that followed the nationwide measles immunization program.
Developing Countries
In some countries like India, over 2 cases of SSPE per 100,000 people are reported each year.